Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stronger Together: Pfizer Decides Against A Split

Executive Summary

The pharma giant's decision not to break up into two separate publicly traded companies as it has been contemplating for several years reflects an improved growth outlook and the inability to unlock trapped value. Now Pfizer can finally get on with business.


Related Content

Pfizer's Oncology Strategy Centers On Three Anchors To Steady The Ship
Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal
Pfizer Essential Health Is Staying Put And Has A Focused Strategy For Growth
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Pfizer Keeps Hands On Consumer Product Wheel In Opting Against Split
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
A Split Won’t “Make Or Break” Pfizer, CEO Read Says
Pfizer’s Allergan Acquisition Paves The Way For A Split – But Delayed


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts